Acute dose-response, double-blind, placebo-controlled pilot study of lercanidipine in patients with angina pectoris

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 5, 2000, Pages 255-265

  Acanfora, Domenico ^d   Gheorghiade, Mihai ^a   Rotiroti, Domenico ^b   Trojano, Luigi ^e   Rengo, Giuseppe ^c   Furgi, Giuseppe ^e   Papa, Antimo ^e   Picone, Costantino ^e   Nicolino, Antonio ^e   Odierna, Luigi ^e   Rengo, Franco ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b S G MOSCATI HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d IRCCS   (Italy)

^e NONE

Author keywords

Angina pectoris; Calcium channel blocker; Hypertension; Lercanidipine; Myocardial ischemia

Indexed keywords

LERCANIDIPINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BICYCLE ERGOMETRY; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0034099651     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)80016-8     Document Type: Article

References (25)

1. 1. Braunwald E, Muller JE, Stone PH. Use of calcium blocking agents in the management of ischemic heart disease. Eur Heart J. 1985;6(Suppl A):A31-A36.
2. 2. Rice KR, Gervino E, Jarisc WR, Stone PH. Effects of nifedipine on myocardial perfusion during exercise in chronic stable angina. Am J Cardiol. 1990;65:1097-1101.
3. 3. Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol. 1994;73:28A-33A.
4. 4. Cone PF, Vetrovec GW, Nesto R, et al. The Nifedipine-Total Ischemia Awareness Program: A national survey of painful and painless myocardial ischemia including results of anti-ischemic therapy. Am J Cardiol. 1984;63:534-539.
5. 5. Frishman WH, Rosenberg A, Katz B. Calcium antagonist in the management of systemic hypertension: The impact of sustained-release drug delivery systems. Coron Artery Dis. 1994;5:4-13.
6. 6. The Danish Study Group on Verapamil in Myocardial Infarction. The Danish Verapamil Infarction Trial II-DAVIT II. Am J Cardiol. 1990;66:779-785.
7. 7. Rengo F, Carbonin PU, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: Results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol. 1996;77:365-369.
8. 8. Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: A randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J. 1986;56:400-413.
9. 9. Opie LH. Mechanisms whereby calcium antagonists may protect patients with coronary artery disease. Eur Heart J. 1997;18(Suppl A):A92-A104.
10. 10. Testa R, Leonardi A, Tajana A, et al. Lercanidipine (Rec 15/2375): A novel 1,4-dihydropyridine calcium antagonist for hypertension. Cardiovasc Drug Rev. 1997;15: 187-219.
11. 11. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovasc Pharmacol. 1997;29(Suppl 1):S19-S24.
12. 12. Meredith PA. Lercanidipine: A novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Exp Opin Invest Drugs. 1999;8: 1043-1062.
13. 13. Van Zwieten PA. The pharmacological properties of lipophilic calcium antagonists. Blood Press. 1998;7(Suppl 2):5-9.
14. 14. Leonetti G. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: Current experience with lercanidipine. High Blood Press. 1999;8:92-101.
15. 15. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens. 1998;16:(12Pt1)1831-1838.
16. 16. Rossoni G, Bernareggi M, De Gennaro Colonna V, et al. Lercanidipine protects the heart from low-flow ischemia damage and antagonizes the vasopressor activity of endothelin-1. J Cardiovasc Pharmacol. 1997;29(Suppl 1):S41-S47.
17. 17. Cargnoni A, Benigno M, Ferrari F, et al. Effects of lercanidipine and its enantiomers on ischemia and reperfusion. J Cardiovasc Pharmacol. 1997;29(Suppl 1):S48-S62.
18. 18. Lindenberg BS, Weiner DA, McCabe CH, et al. Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris. J Am Coll Cardiol. 1983;2:1129-1133.
19. 19. Hopf R, Dowinsky S, Kaltenbach M. Use of the calcium channel blocking agents in treatment of classic exertional angina. In: Stone PH, Antman EM, eds. Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. New York: Futura; 1983: 241-268.
20. 20. Fox KM, Deanfield J, Selwyn A, et al. Treatment of chronic stable angina pectoris with nifedipine. In: Kaltenbach M, Neufeld HN, eds. Proceedings of the 5th International Adalat Symposium. New Therapy of Ischemic Heart Disease and Hypertension. Amsterdam: Excerpta Medica; 1983:197-204.
21. 21. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
22. 22. Scheidt S, LeWinter MM, Hermanovich J, et al. Efficacy and safety of nicardipine for chronic, stable angina pectoris: A multicenter randomized trial. Am J Cardiol. 1986;58: 715-721.
23. 23. Gheorghiade M, Weiner DA, Chakko S, et al. Monotherapy of stable angina with nicardipine hydrochloride: Double-blind, placebo-controlled, randomized study. Eur Heart J. 1989;10:695-701.
24. 24. Gheorghiade M. Nisoldipine and myocardial infarction. N Engl J Med. 1998;339:126-127.
25. 25. Thadani U, ZellenerSR, Glasser S, et al. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Circulation. 1991;84:2398-2408.